The np 3243 MELAS mtDNA mutation in tRNA(leu(UUR)) has been variously propo
sed as a loss-of-function or as a gain-of-function mutation, based on appar
ently contradictory studies in cultured cell lines, A new report describing
the molecular effects of the mutation in vivo now mirrors this variability
. This should prompt a more systematic reinvestigation of cells carrying th
e mutation, in order to separate primary from secondary and pathogenic from
compensatory effects, all of which may contribute to disease phenotype. Nu
clear genetic and developmental background, mitochondrial haplotype, and ep
igenetic effects may all influence the pathological outcome, Defects in bot
h base-modification and aminoacylation of the mutant tRNA could play critic
al roles.